Meta-Analysis Data on Circulating Tumor DNA and Prognosis in Gastric Cancer Surgery

25 studies comprising 60 datasets synthesize evidence on circulating tumor DNA as a biomarker for resectable gastric cancer. The data includes pooled hazard ratios for overall and disease-free survival from a systematic review registered under CRD42025107578. The file was authored by Jidong Bian and last updated on 2026-05-18.

Use Cases

• Validate the prognostic value of ctDNA positivity for survival outcomes based on reported hazard ratios.
• Compare the strength of pre-operative versus post-operative ctDNA measurements as prognostic signals.
• Assess evidence sufficiency for clinical relevance using trial sequential analysis results.
• Conduct subgroup analyses based on detection platforms, sample sources, regions, and cancer stages.

Strengths

• Pooled analysis includes 25 studies and 60 datasets, providing a substantial evidence base.
• Methodology is rigorous, prioritizing multivariate Cox HRs and using random-effects models.
• Results show clear prognostic signals, with post-operative ctDNA HRs of 3.47 for OS and 4.14 for DFS.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Publication bias was present for overall survival outcomes.

Provenance

Source

Systematic review and meta-analysis of published studies, sourced from four major databases.

Collection Method

Data extracted from eligible studies reporting hazard ratios for surgically treated gastric cancer patients.

Time Range

Literature search performed up to May 2025.

Freshness

Last updated 2026-05-18 05:41:23; freshness should be verified.

Geography

Studies included are from multiple regions, as indicated by subgroup analysis.